cPLA2-α and Breast Cancer Prognosis
Author Information
Author(s): Caiazza F, McCarthy N S, Young L, Hill A D K, Harvey B J, Thomas W
Primary Institution: Royal College of Surgeons in Ireland
Hypothesis
cPLA2α activity and expression could be correlated with HER2-overexpressing tumours.
Conclusion
cPLA2α expression is associated with poor prognosis in luminal breast cancer and may serve as a predictive marker for treatment response.
Supporting Evidence
- High cPLA2α mRNA expression correlated with clinical parameters of poor prognosis.
- Patients with high cPLA2α expression had a reduced overall survival compared to those with low expression.
- cPLA2α expression was an independent predictive parameter of poor response to endocrine therapy.
Takeaway
This study found that a protein called cPLA2α is linked to worse outcomes in some breast cancer patients, especially those with certain types of tumors.
Methodology
The study analyzed cPLA2α expression in tissue samples from breast cancer patients using quantitative real-time PCR and gene expression microarrays.
Potential Biases
Potential bias due to the selection of patients and the methods used for determining HER2 status.
Limitations
The study's findings may not be generalizable due to the small sample size and specific patient population.
Participant Demographics
18 breast cancer patients, 15 ER positive and 3 ER negative.
Statistical Information
P-Value
p<0.01
Confidence Interval
95% CI: 0.069–0.862
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website